NOCTURNA THERAPEUTICS
Contact information
- Biodrugs
- Drug development
- Drug discovery
- Gene Therapy
- Musculoskeletal system
- Genetic and rare diseases
- Infectious diseases
- Central nervous system
NoctuRNA has built a patented RNA-based drug platform that enables the generation of novel candidate therapeutical molecules within 2 to 4 weeks. This drug platform is based on artificial circular RNA molecules (circRNA) that efficiently disrupt pathogenic or aberrant RNA secondary structures present in several diseases. We have developed a first-in-class therapeutic approach to tackle some of the world's most intractable diseases.
-
A circRNA validated in vivo targeting SARS-Cov-2.
-
CircRNAs targeting Dengue and West Nile Virus, as well as a broad-spectrum candidate effective against both viruses, validated in vitro.
-
A circRNA validated in vivo for myotonic dystrophy type 1 (Steinert disease), a rare genetic muscular dystrophy.
-
circRNAs targeting multiple neurodegenerative diseases, validated in vitro.
-
Our proprietary production protocol for circRNAs, achieving a circularization yield of 85% - significantly higher than the standard 40%.
- Further development of NoctuRNA’s pipeline for infectious and genetic diseases
- Utilization of NoctuRNA’s platform for the design of circRNA-based therapeutics targeting diseases of interest to potential partner.
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| DM1 circRNA therapy | Gene Therapy | Enfermedades genéticas y raras | Preclinical |